retatrutide latest clinical trial results Lilly orforglipron oral GLP-1 phase 3 weight loss Lilly's retatrutide delivers promising results

Resmetirom received FDA approval for the fibrotic stage, but the steatosis stage, where the vast majority of patients sit, has no approved pharmacological intervention

Their therapeutic potential extends beyond metabolic disorders

Fragment-based synthesis approaches divide a long peptide into smaller segments that are synthesized separately and then joined through a conjugation step

Some animal studies have shown probiotics prevented weight gain and insulin resistance, and promoted the release of GLP-1 [8,9]

Here, we highlight the mechanisms linking T2DM and PD, as well as the links between insulin resistance (IR) and PD patients risk of developing cognitive deficits

This modulation contributes to glycemic regulation, improved insulin sensitivity, and reduced systemic inflammation, addressing key metabolic challenges in an integrated manner